Don't let it get away!
Keep track of the stocks that matter to you.
Help yourself with the Fool's FREE and easy new watchlist service today.
Ligand believes the drug in question, dinaciclib -- originally developed by Ligand acquisition Pharmacopoeia -- offers "significant potential in oncology" and has licensed the drug to Merck for use in treating chronic lymphocytic leukemia.
The news comes too late to save Ligand's third quarter, with the company warning investors this week that absent the $2 million payment, its Q3 revenues are going to fall about 25% short of previous expectations. As the money shifts into Q4, however, Ligand was able to up guidance for Q4 by about 18%, to $13 million.
Two million dollars is about 6.7% of the $30 million in revenues Ligand expects to collect this year. Ligand reports Q3 earnings on Nov. 5.